Agilent Technologies, Inc. (0HAV.L)
USD 103.17
(4.08%)
USD 103.17
(4.08%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 4.91 Billion USD | -5.91% |
| 2022 | 5.22 Billion USD | -1.67% |
| 2021 | 5.31 Billion USD | 11.82% |
| 2020 | 4.75 Billion USD | 1.06% |
| 2019 | 4.7 Billion USD | 18.49% |
| 2018 | 3.97 Billion USD | 10.31% |
| 2017 | 3.59 Billion USD | 0.73% |
| 2016 | 3.57 Billion USD | 7.69% |
| 2015 | 3.31 Billion USD | -39.38% |
| 2014 | 5.47 Billion USD | 1.41% |
| 2013 | 5.39 Billion USD | 0.86% |
| 2012 | 5.35 Billion USD | 12.87% |
| 2011 | 4.74 Billion USD | -26.61% |
| 2010 | 6.46 Billion USD | 26.52% |
| 2009 | 5.1 Billion USD | 4.67% |
| 2008 | 4.87 Billion USD | 12.92% |
| 2007 | 4.32 Billion USD | 16.44% |
| 2006 | 3.71 Billion USD | 38.95% |
| 2005 | 2.67 Billion USD | -23.43% |
| 2004 | 3.48 Billion USD | 0.4% |
| 2003 | 3.47 Billion USD | -2.88% |
| 2002 | 3.57 Billion USD | 53.67% |
| 2001 | 2.32 Billion USD | -26.36% |
| 2000 | 3.16 Billion USD | 53.25% |
| 1999 | 2.06 Billion USD | 4.94% |
| 1998 | 1.96 Billion USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 4.64 Billion USD | -2.48% |
| 2024 Q1 | 4.76 Billion USD | -3.21% |
| 2024 Q3 | 5.09 Billion USD | 9.72% |
| 2023 Q2 | 5.01 Billion USD | -5.63% |
| 2023 Q4 | 4.91 Billion USD | -3.89% |
| 2023 Q3 | 5.11 Billion USD | 2.12% |
| 2023 Q1 | 5.31 Billion USD | 1.59% |
| 2023 FY | 4.91 Billion USD | -5.91% |
| 2022 Q3 | 5.39 Billion USD | 1.13% |
| 2022 Q4 | 5.22 Billion USD | -3.08% |
| 2022 FY | 5.22 Billion USD | -1.67% |
| 2022 Q1 | 5.17 Billion USD | -2.69% |
| 2022 Q2 | 5.33 Billion USD | 3.09% |
| 2021 Q2 | 5.58 Billion USD | 14.74% |
| 2021 Q1 | 4.87 Billion USD | 2.44% |
| 2021 FY | 5.31 Billion USD | 11.82% |
| 2021 Q4 | 5.31 Billion USD | -4.13% |
| 2021 Q3 | 5.54 Billion USD | -0.77% |
| 2020 Q1 | 4.65 Billion USD | -1.08% |
| 2020 Q2 | 4.68 Billion USD | 0.73% |
| 2020 Q3 | 4.56 Billion USD | -2.6% |
| 2020 Q4 | 4.75 Billion USD | 4.14% |
| 2020 FY | 4.75 Billion USD | 1.06% |
| 2019 FY | 4.7 Billion USD | 18.49% |
| 2019 Q4 | 4.7 Billion USD | 21.3% |
| 2019 Q1 | 3.91 Billion USD | -1.36% |
| 2019 Q2 | 3.89 Billion USD | -0.49% |
| 2019 Q3 | 3.87 Billion USD | -0.49% |
| 2018 Q3 | 3.78 Billion USD | -9.26% |
| 2018 FY | 3.97 Billion USD | 10.31% |
| 2018 Q1 | 4.17 Billion USD | 15.92% |
| 2018 Q2 | 4.16 Billion USD | -0.12% |
| 2018 Q4 | 3.97 Billion USD | 5.0% |
| 2017 FY | 3.59 Billion USD | 0.73% |
| 2017 Q3 | 3.65 Billion USD | 0.25% |
| 2017 Q2 | 3.64 Billion USD | 1.93% |
| 2017 Q1 | 3.57 Billion USD | -0.03% |
| 2017 Q4 | 3.59 Billion USD | -1.4% |
| 2016 Q2 | 3.47 Billion USD | 6.79% |
| 2016 FY | 3.57 Billion USD | 7.69% |
| 2016 Q1 | 3.25 Billion USD | -1.93% |
| 2016 Q4 | 3.57 Billion USD | 5.46% |
| 2016 Q3 | 3.38 Billion USD | -2.5% |
| 2015 Q3 | 3.14 Billion USD | -3.26% |
| 2015 Q1 | 3.27 Billion USD | -40.09% |
| 2015 Q4 | 3.31 Billion USD | 5.5% |
| 2015 FY | 3.31 Billion USD | -39.38% |
| 2015 Q2 | 3.25 Billion USD | -0.85% |
| 2014 FY | 5.47 Billion USD | 1.41% |
| 2014 Q1 | 5.19 Billion USD | -3.82% |
| 2014 Q4 | 5.47 Billion USD | 15.46% |
| 2014 Q3 | 4.74 Billion USD | -11.99% |
| 2014 Q2 | 5.38 Billion USD | 3.76% |
| 2013 FY | 5.39 Billion USD | 0.86% |
| 2013 Q4 | 5.39 Billion USD | -1.66% |
| 2013 Q1 | 5.3 Billion USD | -0.92% |
| 2013 Q2 | 5.27 Billion USD | -0.43% |
| 2013 Q3 | 5.48 Billion USD | 3.96% |
| 2012 Q2 | 4.68 Billion USD | 1.91% |
| 2012 FY | 5.35 Billion USD | 12.87% |
| 2012 Q4 | 5.35 Billion USD | 9.56% |
| 2012 Q3 | 4.88 Billion USD | 4.18% |
| 2012 Q1 | 4.6 Billion USD | -2.97% |
| 2011 FY | 4.74 Billion USD | -26.61% |
| 2011 Q4 | 4.74 Billion USD | 4.13% |
| 2011 Q3 | 4.55 Billion USD | -2.88% |
| 2011 Q2 | 4.68 Billion USD | -0.36% |
| 2011 Q1 | 4.7 Billion USD | -27.17% |
| 2010 FY | 6.46 Billion USD | 26.52% |
| 2010 Q3 | 6.29 Billion USD | 22.49% |
| 2010 Q2 | 5.13 Billion USD | 2.68% |
| 2010 Q1 | 5 Billion USD | -2.06% |
| 2010 Q4 | 6.46 Billion USD | 2.7% |
| 2009 Q2 | 4.15 Billion USD | -9.45% |
| 2009 Q1 | 4.59 Billion USD | -5.88% |
| 2009 FY | 5.1 Billion USD | 4.67% |
| 2009 Q3 | 4.08 Billion USD | -1.76% |
| 2009 Q4 | 5.1 Billion USD | 25.02% |
| 2008 Q3 | 4.35 Billion USD | -3.59% |
| 2008 Q2 | 4.51 Billion USD | 5.41% |
| 2008 FY | 4.87 Billion USD | 12.92% |
| 2008 Q4 | 4.87 Billion USD | 11.98% |
| 2008 Q1 | 4.28 Billion USD | -0.79% |
| 2007 Q2 | 3.72 Billion USD | 5.43% |
| 2007 Q4 | 4.32 Billion USD | 15.63% |
| 2007 FY | 4.32 Billion USD | 16.44% |
| 2007 Q1 | 3.53 Billion USD | -4.69% |
| 2007 Q3 | 3.73 Billion USD | 0.21% |
| 2006 Q1 | 3.84 Billion USD | 43.97% |
| 2006 FY | 3.71 Billion USD | 38.95% |
| 2006 Q4 | 3.71 Billion USD | -5.77% |
| 2006 Q3 | 3.93 Billion USD | -1.15% |
| 2006 Q2 | 3.98 Billion USD | 3.62% |
| 2005 Q3 | 3.4 Billion USD | 0.15% |
| 2005 Q4 | 2.67 Billion USD | -21.56% |
| 2005 Q1 | 3.38 Billion USD | -3.01% |
| 2005 Q2 | 3.39 Billion USD | 0.5% |
| 2005 FY | 2.67 Billion USD | -23.43% |
| 2004 Q2 | 3.48 Billion USD | 5.22% |
| 2004 Q1 | 3.31 Billion USD | -4.55% |
| 2004 FY | 3.48 Billion USD | 0.4% |
| 2004 Q3 | 3.41 Billion USD | -2.18% |
| 2004 Q4 | 3.48 Billion USD | 2.2% |
| 2003 FY | 3.47 Billion USD | -2.88% |
| 2003 Q4 | 3.47 Billion USD | 6.21% |
| 2003 Q3 | 3.27 Billion USD | -4.27% |
| 2003 Q1 | 3.42 Billion USD | -4.33% |
| 2003 Q2 | 3.41 Billion USD | -0.15% |
| 2002 Q2 | 3.11 Billion USD | -1.68% |
| 2002 Q3 | 3.43 Billion USD | 10.48% |
| 2002 Q4 | 3.57 Billion USD | 4.07% |
| 2002 FY | 3.57 Billion USD | 53.67% |
| 2002 Q1 | 3.16 Billion USD | 35.93% |
| 2001 Q4 | 2.32 Billion USD | -25.77% |
| 2001 Q3 | 3.13 Billion USD | -9.5% |
| 2001 Q2 | 3.46 Billion USD | -5.54% |
| 2001 FY | 2.32 Billion USD | -26.36% |
| 2001 Q1 | 3.66 Billion USD | 16.04% |
| 2000 Q1 | 2.62 Billion USD | 27.11% |
| 2000 Q2 | 2.67 Billion USD | 2.21% |
| 2000 Q3 | 2.92 Billion USD | 9.18% |
| 2000 FY | 3.16 Billion USD | 53.25% |
| 2000 Q4 | 3.16 Billion USD | 8.03% |
| 1999 Q4 | 2.06 Billion USD | 0.0% |
| 1999 FY | 2.06 Billion USD | 4.94% |
| 1998 FY | 1.96 Billion USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| uniQure N.V. | 624.01 Million USD | -688.117% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -3800.11% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | -696.172% |
| bluebird bio, Inc. | 424.62 Million USD | -1058.201% |
| Imunon, Inc. | 8.53 Million USD | -57552.448% |
| Dynavax Technologies Corporation | 375.02 Million USD | -1211.383% |
| Illumina, Inc. | 4.36 Billion USD | -12.643% |
| Myriad Genetics, Inc. | 312.9 Million USD | -1471.748% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | -104.47% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -908.901% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 90.521% |
| Biogen Inc. | 12.04 Billion USD | 59.171% |
| Nektar Therapeutics | 267.04 Million USD | -1741.63% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -7052.518% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | -382.441% |
| Perrigo Company plc | 6.04 Billion USD | 18.592% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | -40.294% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -1757.707% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 76.09% |
| Editas Medicine, Inc. | 150.05 Million USD | -3177.443% |
| Verastem, Inc. | 71.18 Million USD | -6808.759% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 92.858% |
| Waters Corporation | 3.47 Billion USD | -41.464% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -13880.68% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -2412.542% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -1817.506% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -13087.815% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | -160.204% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -5866.057% |
| Evolus, Inc. | 209.68 Million USD | -2245.401% |
| Adicet Bio, Inc. | 37.12 Million USD | -13148.922% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -12125.924% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 30.802% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | -644.261% |
| FibroGen, Inc. | 585.72 Million USD | -739.639% |
| OPKO Health, Inc. | 622.47 Million USD | -690.067% |
| Homology Medicines, Inc. | 118.53 Million USD | -4049.056% |
| Geron Corporation | 146.12 Million USD | -3265.566% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | -21.416% |
| Exelixis, Inc. | 678.44 Million USD | -624.893% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -24403.014% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -39137.275% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -1860.862% |
| Zoetis Inc. | 9.29 Billion USD | 47.09% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | -1137.983% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -9900.813% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 4.501% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -10051.718% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | -88.908% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -4183.524% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | -198.158% |
| Blueprint Medicines Corporation | 918.64 Million USD | -435.356% |
| Insmed Incorporated | 1.66 Billion USD | -195.951% |
| TG Therapeutics, Inc. | 169.08 Million USD | -2808.596% |
| Incyte Corporation | 1.59 Billion USD | -208.867% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | -314.811% |